These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30426719)

  • 1. Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design.
    Reuter SE; Evans AM; Ward MB
    CPT Pharmacometrics Syst Pharmacol; 2019 Jan; 8(1):26-33. PubMed ID: 30426719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection.
    Gutfraind A; Galvani AP; Meyers LA
    JAMA Pediatr; 2015 Apr; 169(4):341-8. PubMed ID: 25706618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
    La Via WV; Notario GF; Yu XQ; Sharma S; Noertersheuser PA; Robbie GJ
    Pulm Pharmacol Ther; 2013 Dec; 26(6):666-71. PubMed ID: 23523663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
    Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
    Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of Palivizumab.
    Lavoie PM; Solimano A; Taylor R; Kwan E; Claydon J; Turvey SE; Marr N
    JAMA Pediatr; 2016 Feb; 170(2):174-6. PubMed ID: 26720836
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.
    Claydon J; Sur A; Callejas A; Ladd M; Kwan E; Taylor R; Turvey SE; Solimano A; Lavoie PM; Marr N
    PLoS One; 2017; 12(4):e0176152. PubMed ID: 28437470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab.
    Paes B; Saleem M; Kim D; Lanctôt KL; Mitchell I
    Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1561-1568. PubMed ID: 31119575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
    Diehl JL; Daw JR; Coley KC; Rayburg R
    J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.
    Resch B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2138-2149. PubMed ID: 28605249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors related to compliance with palivizumab prophylaxis for respiratory syncytial virus (RSV) infection - data from Poland.
    Borecka R; Lauterbach R; Helwich E
    Dev Period Med; 2016; 20(3):181-190. PubMed ID: 27941187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimum dosage regimen of palivizumab?
    Zaaijer HL; Vandenbroucke-Grauls CM; Franssen EJ
    Ther Drug Monit; 2002 Jun; 24(3):444-5. PubMed ID: 12021640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.
    Ambrose CS; Chen X; Kumar VR
    Hum Vaccin Immunother; 2014; 10(10):2785-8. PubMed ID: 25483483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RSV Hospitalizations in Comparison With Regional RSV Activity and Inpatient Palivizumab Administration, 2010-2013.
    Glick AF; Kjelleren S; Hofstetter AM; Subramony A
    Hosp Pediatr; 2017 May; 7(5):271-278. PubMed ID: 28381595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
    Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
    Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis.
    Resch B; Bramreiter VS; Kurath-Koller S; Freidl T; Urlesberger B
    Eur J Clin Microbiol Infect Dis; 2017 Jun; 36(6):1057-1062. PubMed ID: 28078558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
    Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palivizumab use in very premature infants in the neonatal intensive care unit.
    Wu SY; Bonaparte J; Pyati S
    Pediatrics; 2004 Nov; 114(5):e554-6. PubMed ID: 15520088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.